01 — At a Glance
The Amine Guy Who Built a Moat. Then Overcapacity Showed Up With a Bulldozer.
- 52-Week High / Low₹2,449 / ₹1,250
- FY25 Revenue (Full Year)₹1,441 Cr
- FY25 PAT (Full Year)₹149 Cr
- Full-Year EPS (FY25)₹29.12
- Q3 FY26 EPS₹8.26
- Book Value₹282
- Price to Book4.53x
- Dividend Yield0.78%
- Debt / Equity0.00x (Debt-Free!)
- 1-Year Returns-21.4%
The Auditor’s Reality Check: Nine months ended Dec 31, 2025: ₹1,172 crore revenue. Flat growth. Q3 PAT down 3.4% YoY despite revenue up 6.4%. Margins compressed. Chinese imports increased. Methylamines market entering what management calls a “long item” — industry speak for “buckle up, this is going to suck for a while.” Stock down 21% in one year. Meanwhile, the company sits debt-free with ₹165 crore in cash. The irony? They’re not buying back stock. They’re just… holding.
02 — Introduction
Specialty Amines: The Unsexy Business That Everyone Forgot Had a China Problem
Let me introduce you to Alkyl Amines Chemicals. Founded in 1979 by Yogesh Kothari. They make aliphatic amines — which are essentially ammonia derivatives with some chemical tweaks. Sounds thrilling, I know. But wait. These little molecules go into pharmaceuticals (including GLP-1 diabetes drugs everyone’s screaming about), agrochemicals, dyes, pigments, water treatment, paints, polymers — basically anything that needs to be chemically sophisticated.
The company is a monopoly in several products. They’re the sole global producer of certain specialty amines. ROCE of 18.7% — respectable. ROE of 14%. A market cap of ₹6,532 crore. Debt-free balance sheet. Operating cash flow of ₹263 crore per year. They’ve never posted a loss. They’ve built something real.
Then 2025 happened. The US decided to wage a trade war. China decided to dump everything into non-US markets because they couldn’t sell to America anymore. Methylamines market developed massive overcapacity. A fourth competitor (Aarti Drugs) came online. And suddenly, the “boring oligopoly” became the “scary commodity price fight.”
Q3 FY26 results (ended Dec 31, 2025) show the pain. Revenue flat YoY. Margins compressed. Volume pressure on methylamines. Pricing pressure on ethylamines. Management’s concall was refreshingly honest: “We have been affected in four ways” — direct US exports down, customers’ US sales down, Chinese competition up, and sanctions on distributors. It’s geopolitical roulette, and Alkyl Amines is holding the wheel.
From the Concall (Nov 2025): “We have been affected in four ways… and to some extent, this is the cause of the demand slackness.” Management linked everything to US trade actions. They didn’t sugarcoat it. That’s either refreshing honesty or a warning sign depending on your mood.
03 — Business Model: Why Nobody Knows What They Do (But They Should)
Make Amines. Sell Everywhere. Repeat. Until China Shows Up.
Alkyl Amines operates 20+ production plants across 3 manufacturing sites in Patalganga (Maharashtra), Kurkumbh (Maharashtra), and Dahej (Gujarat). Combined capacity: 158,000 metric tonnes per annum (MTPA). Average utilization: 60–70% across plants — meaning they have headroom, but also that demand hasn’t been screaming.
Revenue mix (FY25): Amines & Amine Derivatives = 79%. Specialty Chemicals & Others = 21%. Geography: Domestic = 76%. Exports = 24%. They sell to pharma, agro, dyes, rubber, surfactants, mining, water treatment, paints, polymers, personal care — basically the entire chemical ecosystem.
They make four product categories: ethylamines (higher margin, less competitive, domestic-focused), methylamines (commodity-like, highly competitive, Chinese dumping threat), acetonitrile (niche, specialty, under anti-dumping duty protection), and derivatives (added value, margin-protective). They also make di-ethyl ketone (DEK) and other intermediates.
The moat used to be: oligopolistic market, technical capabilities, production scale, regulatory approvals for pharma. The problem now is: Chinese overcapacity is so vast that a moat doesn’t matter when you’re playing checkers against someone with infinite pawns.
Domestic Revenue %76%FY25 Share
Export Revenue %24%FY25 Share
Capacity Utilization60-70%Avg Across Plants
The China Elephant: Management stated explicitly on the concall that imports surged before anti-dumping duty implementation, creating inventory overhang. Chinese players then cut prices further. The ADD (anti-dumping duty) benefits have been “muted” so far. Real benefits expected Q4 onwards “mainly volume.”
💬 Do you think specialty chemicals in India can survive the China commodity-price death spiral, or is this a structural decline? Drop your views.
04 — Financials Overview
Q3 FY26: The Numbers That Tell a Story You Don’t Want to Hear
